---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-045865"
form_type: "8-K"
ticker: "ZURA"
cik: "0001855644"
company_name: "Zura Bio Ltd"
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:32:37.101356+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Zura Bio Q1 net loss $17.4M; cash $170.6M; trial on track

## Summary
- Net loss $17.4M ($0.19/sh) vs $7.7M ($0.02/sh) in Q1 2024; R&D spend $10.5M (+192% YoY).
- Cash and equivalents $170.6M; runway expected to fund operations through 2027.
- Phase 2 TibuSURE trial for systemic sclerosis continues; HS Phase 2 expected Q2 2025.
- Appointed Kate Dingwall as SVP of Development Operations to support clinical execution.
- G&A expenses $8.8M, increased $4.0M YoY due to compensation and professional fees.

## SEC filing metadata
- accession: 0001104659-25-045865
- form_type: 8-K
- ticker: ZURA
- cik: 0001855644
- company_name: Zura Bio Ltd
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855644/000110465925045865/0001104659-25-045865-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855644/000110465925045865/tm2514121d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-045865
- JSON: https://secwatch.observer/filing/0001104659-25-045865.json
- Plain text: https://secwatch.observer/filing/0001104659-25-045865.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.